Transgene SA · EURONEXT:TNG
Transgene SA — Rodman & Renshaw (May 2005)
28 slides from Transgene SA's conference presentation, May 4, 2005
Slide 1: Transgene: New management – New strategy – New future
TRANSGENE New management – New strategy – New future Rodman & Renshaw - May 4, 2005 1 transgene
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s capital requirements and prospects. Statements that are not historical facts are based on the Company's current expectations, beliefs, estimates, forecasts and assumptions. The
Slide 3: Agenda
Agenda § INTRODUCTION § TRANSGENE STRATEGIC DIRECTION • Transgene transformed • Transgene in 2007 • Short term objectives § THE CLINICAL PIPELINE • The pipeline today • New clinical data § 2004 FINANCIAL RESULTS § CONCLUSION 3 transgene
Slide 4: Transgene Transformed
Transgene Transformed §December, 2004: New CEO with strong biotech experience and track record §February, 2005: New CSO with impressive background in immunology and oncology. §February, 2005: Strong Phase II data in lung and prostate cancers §March, 2005: Company refocused on immunotherapy to treat
Slide 5: The future -- Transgene in 2007
The future -- Transgene in 2007 -- § Three Phase III trials ongoing: • MVA-Muc1-IL2 to treat NSCLC • MVA-HPV-IL2 in CIN2/3 related to HPV16 • Ad-IFNg to treat cutaneous T cell lymphoma (CTCL) § MVA Muc1-IL2 in Prostate in Phase IIb § MVA-HCV in Phase II to treat chronic carriers § Partnerships for t
Slide 6: 2005 Clinical Development Plan
2005 Clinical Development Plan Indication Preclinical Phase I Phase II Next step MVA-MUC1-IL2 Lung Phase IIb MVA-HPV-IL2 CIN 2/3 (6 month follow up) Phase IIb Ad-IFNγ Cutaneous T-Cell Lymphoma (CTCL) Phase II / III MVA-HCV Hepatitis C Phase I / II Myodys® Duchenne / Becker muscular dystrophy AFM Pha
Slide 7: Short Term Objectives
Short Term Objectives § Completion of organizational refocusing to achieve clinical proof of concept ASAP § Re-deploy research programs to support product strategy • Development of cancer & infectious disease drug candidates • Broadening technology platforms beyond viral vectors § Leverage internal
Slide 8: Latest Clinical Developments
Latest Clinical Developments 8 transgene
Slide 9: MVA-MUC1-IL2 Product profile
MVA-MUC1-IL2 Product profile § Recombinant MVA (Modified Virus Ankara) • non-replicative, highly immunogenic poxvirus § Expressing MUC1 tumor-associated antigen • MUC1 is found in most adenocarcinoma • Associated with poor prognosis Cell membrane § Expressing human IL-2 cDNA GalNAc Sialic Ac (Tn) ST
Slide 10: MVA-MUC1-IL2 Phase II Interim Results
MVA-MUC1-IL2 Phase II Interim Results § Interim Results (February 2005) § End points reached in Non Small-cell Lung Cancer MVA-Muc1-IL2 + chemo : 35 evaluable patients 13/35 (37%) PR (validated by central reading) 11/35 (31%) SD > 12w 24/35 (68%) Clinical benefit Time to Progression 6.4 months Overa
Slide 11: MVA-MUC1-IL2 in NSCLC: Comparison With Published Clinical Studies
MVA-MUC1-IL2 in NSCLC : Comparaison With Published Clinical Studies Using Navelbine / Cisplatine regimen Study % response Study TTP Study Overall survival (months) (months) Gebbia 44 MVA-Muc1-IL2 + 6.4 MVA-Muc1-IL2 + >12 MVA-Muc1-IL2 + 37 % chemo chemo chemo Gridelli 5.3 Fossela 10.1 Souquet 34.6 Fo
Slide 12: MVA-MUC1-IL2 Future direction
MVA-MUC1-IL2 Future direction § Final Phase II data presentation at ASCO (13-17 May 2005) § Next step: to demonstrate clinical benefit in lung cancer patients through a 150 patients randomized Phase IIb controlled study evaluating the combination of MVA-MUC1-IL2 to standard chemotherapies versus che
Slide 13: MVA-HPV-IL2 Product profile
MVA-HPV-IL2 Product profile § Recombinant MVA (Modified Virus Ankara) • non-replicative, highly immunogenic poxvirus § Expressing early genes of Human Papilloma Virus 16 (HPV16) • CIN (cervical intraepithelial neoplasia) due to HPV: pre-cancerous stage of cervix cancer • “HPV is the necessary cause
Slide 14: MVA-HPV-IL2 Clinical Trial Design - Completed Phase II
MVA-HPV-IL2 Clinical Trial Design - Completed Phase II § Multicenter study in France § CIN2/3 in HPV16+ patients § 3 sub-cutaneous injections of MVA-HPV-IL2, on Days 1-8-15 § 2 doses tested: 5x105 pfu and 5x107 pfu § Standard treatment (conisation) on Week 6-8 14 transgene
Slide 15: MVA-HPV-IL2 Final Results of Completed Phase II
MVA-HPV-IL2 Final Results of Completed Phase II Summary table of MVA-HPV-IL2 dose (pfu) secondary efficacy endpoints 5x105 5x107 Patients treated 14 17 Patients analyzed for efficacy 13 16 Viral clearance 0 4 Partial regression of histology signs 0 5 Reduction of grade (to CIN1) 0 2 Limited extent o
Slide 16: MVA-HPV-IL2 Clinical Trial Design - Phase IIb - Ongoing
MVA-HPV-IL2 Clinical Trial Design - Phase IIb - Ongoing § CIN2/3 in HPV 16-positive patients § Study design • Open-label, 5x107 pfu • 18 CIN2/3 patients § Treatment plan • Up to 6-month assessment period to study efficacy • Follow-up every 2 months : Cytology + virology + colposcopy ± biopsy • Respo
Slide 17: Ad-IFNγ Product Profile
Ad-IFNγ Product Profile § Recombinant adenovirus vector containing the sequence coding for the human IFN-g § Mechanism of action • Direct action on tumor cells: antiproliferative, induction of apoptosis • Indirect actions on tumors: immune stimulation, antiangiogenic activities § Clinical positionin
Slide 18: Ad-IFNγ Clinical Trial Design
Ad-IFNγ Clinical Trial Design Phase I/II : Primary Cutaneous Lymphoma § Study design Dose escalation 3 dose levels 3.109 tp → 3.1011 tp 3 patients / dose level (Phase I) + 9 patients at highest dose + up to 18 patients (Phase I / II) § Treatment plan Intra-tumoral administration Weekly injections (D
Slide 19: Ad-IFNγ Efficacy Results – February 28, 2005
Ad-IFNγ Efficacy Results – February 28, 2005 § Interim data first 20 patients • Clinical responses observed locally 7 CR and 3 PR out of 18 evaluable patients (56%) • Distant clinical responses : 2 CR – 1 PR out of 12 evaluable patients • Overall response rate (53%) 19 transgene
Slide 20: Ad-IFNγ Future Direction
Ad-IFNγ Future Direction § Clinical development Cutaneous Lymphoma: • Phase II / III study (Q1 06 – Q1 08) in CTCL patients • Placebo controlled – 2 step study – 75 patients § Regulatory strategy : • U.S.: • IND preparation and filing in process • Orphan drug designation submission Q4 05 • E.U.: • P
Slide 21: Phase I & Preclinical Pipeline
Phase I & Preclinical Pipeline § MVA-HCV monotherapy • Chronic carriers (naïve and non-responders) • Start US Phase I/II trials in Q1 2006 • Phase II expected to begin by early 2007 • Prime-boost combinations under investigation in preclinicals. § Duchenne muscular dystrophy • First ever gene based
Slide 22: Financial Information
FINANCIAL INFORMATION 22 transgene
Slide 23: Statement of Operations
Statement of Operations US GAAP; in € million ; unaudited 2004 Revenues 2.5 Operating expenses (24.2) R&D (20.0) G&A (4.2) Loss from operations (21.7) Interest income 0.5 Income tax benefit 0.7 Net loss (20.5) Cash 14.6 2004 burn rate: 20.3 M€ 2005 expected burn rate: 20.0 M€ 23 transgene
Slide 24: Conclusion
CONCLUSION 24 transgene
Slide 25: Milestones and Newsflow
Milestones and Newsflow PRODUCT INDICATION MILESTONE DATE Asco presentation of results for Lung & Prostate Q2 2005 MVA-MUC1-IL2 NSCLC / Lung Start of Phase IIb trial Q4 2005 MVA-HPV-IL2 CIN 2/3 Results on Phase II trial Q4 2005 Feedback on IND review Q2 2005 Ad-IFNg CTCL Final results on 36 patients
Slide 26: Investment Case
Investment Case § Clinical pipeline with 3 phase II in active development § Products with large market potential aiming at fullfilling large unmet medical needs § Focused strategy in therapeutic vaccine field, leading to rich newsflow in 2005 § Large reservoir of opportunities (internal product cand
Slide 27: Senior Management
Senior Management Dr. Christophe MERIEUX Philipe ARCHINARD Chairman Chief Executive Officer Philippe PONCET Jean-Yves BONNEFOY Chief Scientific Officer Chief Financial Officer 27 transgene
Slide 28: Transgene contact details
Transgene 11 rue de Molsheim 67082 Strasbourg Cedex France Contact : communication@transgene.fr Tel : +33-(0)3.88.27.91.02 Web Site : www.transgene.fr 28 transgene